IGF2BP3 promotes the proliferation and cisplatin resistance of bladder cancer by enhancing the mRNA stability of CDK6 in an m6A dependent manner

被引：0

作者：

Song, Qiang ^{[1
]}

Wang, Wei ^{[1
]}

Yu, Hao ^{[1
]}

Zhou, Zijian ^{[1
]}

Zhuang, Juntao ^{[1
]}

Lv, Jiancheng ^{[1
]}

Jiang, Linjing ^{[1
]}

Yang, Xiao ^{[1
]}

Lu, Qiang ^{[1
]}

Yang, Haiwei ^{[1
]}

机构：

[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Urol, Nanjing 210029, Peoples R China

来源：

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES | 2025年 / 21卷 / 05期

基金：

中国国家自然科学基金;

关键词：

IGF2BP3; bladder cancer; CDK6; m6A; chemotherapy; CELL-CYCLE ARREST; ONCOGENIC TRANSCRIPTS; BREAST-CANCER; APOPTOSIS; N-6-METHYLADENOSINE; METHYLATION; PROGRESSION; INHIBITORS; READERS; GROWTH;

D O I：

10.7150/ijbs.103522

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Cisplatin-based chemotherapy is a primary treatment for bladder cancer, yet the development of chemoresistance poses a significant therapeutic challenge. Insulin-like growth factor II mRNA binding protein 3 (IGF2BP3) is an RNA-binding protein and a key m6A reader that regulates various cancers through m6A-dependent mechanisms. However, its role in chemotherapy resistance in bladder cancer remains unclear. Our in vivo and in vitro experiments identified IGF2BP3 as a key regulator of cisplatin resistance in bladder cancer. We demonstrated that IGF2BP3 enhances the stability of CDK6 mRNA in an m6A-dependent manner, leading to increased CDK6 expression. This, in turn, promoted tumor cell proliferation and resistance to cisplatin chemotherapy. Moreover, we showed that the CDK6 inhibitor palbociclib effectively suppresses the pro-growth and chemoresistant effects induced by IGF2BP3 overexpression. These results suggested that the IGF2BP3/m6A/CDK6 axis plays a pivotal role in bladder cancer progression and chemoresistance, and that targeting this pathway with CDK6 inhibitors such as palbociclib may offer a promising therapeutic strategy for overcoming cisplatin resistance in bladder cancer.

引用

页码：2048 / 2066

页数：19

共 69 条

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA Cancer J Clin, 71, 3, pp. 209-249, (2021)
[2] Dyrskjot L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, Et al., Bladder cancer, Nature reviews Disease primers, 9, 1, (2023)
[3] Comperat E, Amin MB, Cathomas R, Choudhury A, De Santis M, Kamat A, Et al., Current best practice for bladder cancer: a narrative review of diagnostics and treatments, Lancet (London, England), 400, 10364, pp. 1712-1721, (2022)
[4] Grayson M., Bladder cancer, Nature, 551, 7679, (2017)
[5] Babjuk M, Burger M, Capoun O, Cohen D, Comperat EM, Dominguez Escrig JL, Et al., European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ), Eur Urol, 81, 1, pp. 75-94, (2022)
[6] Li F, Zheng Z, Chen W, Li D, Zhang H, Zhu Y, Et al., Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms, Drug Resist Updat, 68, (2023)
[7] Trenta P, Calabro F, Cerbone L, Sternberg CN., Chemotherapy for Muscle-Invasive Bladder Cancer, Curr Treat Options Oncol, 17, 1, (2016)
[8] Lin H, Wang Y, Wang P, Long F, Wang T., Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance, Molecular Cancer, 21, 1, (2022)
[9] Yi Y-C, Chen X-Y, Zhang J, Zhu J-S., Novel insights into the interplay between m6A modification and noncoding RNAs in cancer, Molecular Cancer, 19, 1, (2020)
[10] Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, Et al., N6-methyladenosine-dependent regulation of messenger RNA stability, Nature, 505, 7481, pp. 117-120, (2014)

← 1 2 3 4 5 6 7 →